Aspirin study for kidney patients halted early – did the risks outweigh the benefits?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females aged 18 years and over at the date of screening * .Subjects with CKD (reduced eGFR and/or albuminuria) defined as: • estimated glomerular filtration rate \[eGFR\] \<60mL/min/1.73m2 for at least 90 days, and/or • kidney disease code on the GP electronic patient AND most recent eGFR in CKD-defining range (\<60mL/min/1.73m2), and/or • albuminuria or proteinuria (defined as urine albumin:creatinine ratio \[ACR\] ≥3mg/mmol, and/or urine protein:creatinine ratio \[PCR\] ≥15mg/mmol, and/or +protein or greater on reagent strip) * Subjects who are willing to give permission for their paper and electronic medical records to be accessed by trial investigators * Subjects who are willing to be contacted and interviewed by trial investigators * Subjects who can communicate well with the investigator or designee, understand the requirements of the study and understand and sign the written informed consent Exclusion Criteria * Subjects with CKD GFR category 5 * Subjects with pre-existing cardiovascular disease (angina, myocardial infarction, stroke, transient ischaemic attack (TIA), significant peripheral vascular disease, coronary or peripheral revascularisation for atherosclerotic disease) * Subjects with a current pre-existing condition associated with increased risk of bleeding other than CKD * Subjects currently prescribed anticoagulants or antiplatelet agent, or taking over the counter (OTC) aspirin continuously * Subjects who are currently and regularly taking other drugs with a potentially serious interaction with aspirin * Subjects with a known allergy to aspirin or definite previous clinically important adverse reaction * Subjects with poorly controlled hypertension (systolic blood pressure \[BP\] ≥180 mmHg and/or diastolic BP ≥105 mmHg) * . Subjects with other conditions which in the opinion of their General Practitioner (GP) would preclude prescription of aspirin in routine clinical practice, for example significant anaemia or thrombocytopenia * Subjects who are pregnant or likely to become pregnant during the study period * Subjects with malignancy that is life-threatening or likely to limit prognosis, other life-threatening co-morbidity, or terminal illness * Subjects whose behaviour or lifestyle would render them less likely to comply with study medication * Subjects in prison * Subjects currently participating in another clinical trial of an investigational medicinal product or who have taken part in such a trial in the last three months (Covid-19 vaccine studies are acceptable)